Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%

被引：0
作者：
Merker, Ludwig
Lund, Soren S.
Hantel, Stefan
Salsali, Afshin
Kim, Gabriel
Broedl, Uli C.
Woerle, Hans J.
Hach, Thomas
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1079-P
引用
收藏
页码：A280 / A281
页数：2
相关论文
共 50 条
  • [21] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
    Kovacs, Christopher Simon
    Seshiah, Veeraswamy
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Stella, Peter
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [22] COORDINATION OF HBA1C AND LVDD IN T2DM WITH IHD
    Mukhtarova, Shahnoza
    Trigulova, Raisa
    Akhmedova, Dilafruz
    Alimova, Dilnoza
    Akhmedova, Shokhistakhon
    ATHEROSCLEROSIS, 2024, 399
  • [23] An average HbA1C of <7.0 is achievable in patients with T2DM
    Hood, RC
    DIABETES, 2002, 51 : A485 - A485
  • [24] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    He, J.
    Neslusan, C.
    Johansen, P.
    Worbes-cerezo, M.
    VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [25] Implications of Using the UKPDS HbA1c Equation in Economic Modeling of Type 2 Diabetes Mellitus (T2DM)
    Willis, Michael
    Asseburg, Christian
    Johansen, Pierre
    Schroeder, Melanie
    Neslusan, Cheryl
    DIABETES, 2016, 65 : A581 - A581
  • [26] Efficacy and Safety of Vildagliptin in Triple Combination With Metformin Plus Sulfonylurea in Subgroup of Patients With T2DM and Baseline HbA1c
    Lukashevich, Valentina
    Araga, Mako
    Kothny, Wolfgang
    DIABETES, 2013, 62 : A294 - A294
  • [27] Effect of empagliflozin (EMPA) on diabetic ketoacidosis (DKA) in patients with type 2 diabetes (T2DM): pooled clinical trial data
    Lund, S.
    Solimando, F.
    Kohler, S.
    Zeller, C.
    Kaspers, S.
    DIABETOLOGIA, 2016, 59 : S26 - S27
  • [28] Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM)
    Dejager, Sylvie
    Lebeaut, Alexandre
    Couturier, Andre
    Schweizer, Anja
    DIABETES, 2006, 55 : A29 - A29
  • [29] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
    Haering, Hans-Ulrich
    Merker, Ludwig
    Vedel, Anita
    Roux, Christiansen Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A280 - A280
  • [30] Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-on to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)
    Ridderstrale, Martin
    Andersen, Knut Robert
    Zeller, Cordula
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A70 - A70
12345